

Media Release

Zug, 2 June 2017

Publication of Annual Report 2016/2017 and Invitation to the Ordinary Shareholders' Meeting

The invitation to the 16th Ordinary Shareholders' Meeting on 26 June 2017 has been sent to the shareholders today.

The detailed invitation with all motions of the Board of Directors is enclosed to this media release and displayed on the Company's website <http://www.hbmhealthcare.com>.

Agenda for the 16th Ordinary Shareholders' Meeting on 26 June 2017

1. Statutory financial statements and group financial statements 2016/2017; reports of the auditors
2. Discharge from liability of the members of the Board of Directors and Management
3. Appropriation of results
 - Appropriation of disposable profit of CHF 81'422'808
 - Withholding tax-exempt cash distribution from the reserve from capital brought in of CHF 5.80 per entitled share
4. Elections regarding the Board of Directors
 - Re-elections of the Chairman and of the Members of the Board of Directors
 - Re-election of the members of the Compensation Committee
5. Compensation to the Board of Directors and to the Management
6. Appointment of auditors
7. Appointment of independent proxy-holder
8. Reduction of share capital by means of cancellation of own shares
9. Amendment of the Articles of Association Amendment in line with simplification due to consolidated accounts

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA

HBM Healthcare Investments

10. Miscellaneous

HBM Healthcare Investments also published today its Annual Report 2016/2017 on the Company's website <http://www.hbmhealthcare.com/en/investoren/finanzberichte/finanzberichte-2016-2017.php>

For further information, please contact Dr Andreas Wicki, tel.: +41 41 710 75 77, andreas.wicki@hbmhealthcare.com

Information on HBM Healthcare Investments Ltd

HBM Healthcare Investments actively invests in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. The company holds and manages an international portfolio of promising companies. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided on their strategic directions. This is what makes HBM Healthcare Investments an interesting alternative to investing in big pharma and biotech companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM Healthcare Investments Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM Healthcare Investments Ltd

Bundesplatz 1 CH-6300 Zug | Tel: +41 41 710 75 77 | Fax: +41 41 710 75 78 | info@hbmhealthcare.com
www.hbmhealthcare.com